Skip to main content

Congenital Fibrinogen Deficiency

0
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Octapharma
OctapharmaAustria - Vienna
4 programs
FibrygaN/A1 trial
OctafibrinPHASE_21 trial
OctafibrinPHASE_31 trial
OctafibrinPHASE_31 trial
Active Trials
NCT03793426Terminated7Est. May 2025
NCT01575756Completed22Est. Jan 2015
NCT02408484Completed15Est. Jun 2019
+1 more trials
CSL Behring
CSL BehringIL - Bradley
1 program
FCHN/A1 trial
Active Trials
NCT02427217Completed22Est. Dec 2017
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
FCHN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OctapharmaOctafibrin
OctapharmaOctafibrin
OctapharmaOctafibrin
OctapharmaFibryga
CSL BehringFCH

Clinical Trials (5)

Total enrollment: 91 patients across 5 trials

NCT02408484OctapharmaOctafibrin

Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency

Start: Dec 2015Est. completion: Jun 201915 patients
Phase 3Completed
NCT02267226OctapharmaOctafibrin

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

Start: Sep 2014Est. completion: Feb 201825 patients
Phase 3Completed
NCT01575756OctapharmaOctafibrin

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Start: Jun 2013Est. completion: Jan 201522 patients
Phase 2Completed
NCT03793426OctapharmaFibryga

Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

Start: Jan 2021Est. completion: May 20257 patients
N/ATerminated
NCT02427217CSL BehringFCH

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

Start: May 2015Est. completion: Dec 201722 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.